SXT SENSIENT TECHNOLOGIES CORP
Industrial Organic Chemicals · NYSE · SEC CIK 310142 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.5%
TTM net income YoY21.7%
TTM EPS YoY21.4%
Revenue 3-yr CAGR6.3%
Net income 3-yr CAGR9.7%
Margins
Gross margin35.1%
Operating margin14.5%
Net margin9.7%
FCF margin-1.0%
EBITDA margin18.1%
Returns
ROE13.7%
ROA7.2%
ROIC (approx.)10.0%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets48.0%
Debt / equity0.61x
Current ratio3.97x
Interest coverage7.95x
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio2.1%
Payout ratio41.2%
Capex / revenue7.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.61B | $1.56B |
| Cost of revenue | $1.07B | $1.05B |
| Gross profit | $539.30M | $507.09M |
| R&D expense | $52.90M | $49.10M |
| SG&A expense | $332.17M | $315.51M |
| Operating income | $207.13M | $191.58M |
| Interest expense | $29.58M | $28.78M |
| Pretax income | $177.55M | $162.80M |
| Income tax | $43.06M | $38.13M |
| Net income | $134.49M | $124.67M |
| EBITDA | $268.23M | $251.91M |
| EPS (basic) | 3.18 | 2.96 |
| EPS (diluted) | 3.16 | 2.94 |
| Dividends declared per share | 1.64 | 1.64 |
| Weighted avg. shares (diluted) | 42.59M | 42.40M |
| Balance sheet | ||
| Cash & equivalents | $36.53M | $26.63M |
| Receivables | $305.38M | $290.09M |
| Inventory | $678.22M | $600.30M |
| Current assets | $1.08B | $961.89M |
| PP&E, net | $539.30M | $491.59M |
| Goodwill | $439.71M | $411.77M |
| Intangibles | $10.12M | $11.88M |
| Total assets | $2.24B | $2.02B |
| Current liabilities | $263.58M | $270.64M |
| Short-term debt | $352,000 | $19.85M |
| Long-term debt | $709.23M | $613.52M |
| Total debt | $709.58M | $633.37M |
| Total liabilities | $1.05B | $962.81M |
| Shareholders' equity | $1.19B | $1.06B |
| Net debt | $673.05M | $606.75M |
| Cash flow statement | ||
| Operating cash flow | $127.83M | $157.15M |
| Capital expenditure | $89.41M | $59.21M |
| Free cash flow | $38.42M | $97.94M |
| Investing cash flow | -$92.68M | -$59.21M |
| Financing cash flow | -$35.03M | -$81.55M |
| Depreciation & amortization | $61.10M | $60.33M |
| Stock-based compensation | $13.95M | $10.08M |
| Dividends paid | $69.61M | $69.40M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.